ID   PC-9/GR2
AC   CVCL_DI29
SY   PC-9 GR2; PC9-GR2
DR   cancercelllines; CVCL_DI29
DR   GEO; GSM481162
DR   GEO; GSM1960268
DR   GEO; GSM1960269
DR   GEO; GSM1960270
DR   GEO; GSM1960271
DR   Progenetix; CVCL_DI29
DR   Wikidata; Q54938495
RX   PubMed=20118985;
RX   PubMed=26828195;
CC   Population: Chinese; Han and Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Unspecified; Note=Responsible for gefitinib resistance (PubMed=20118985).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 10-04-25; Version: 16
//
RX   PubMed=20118985; DOI=10.1038/onc.2009.526; PMCID=PMC2859699;
RA   Ercan D., Zejnullahu K., Yonesaka K., Xiao Y., Capelletti M.,
RA   Rogers A., Lifshits E., Brown A., Lee C., Christensen J.G.,
RA   Kwiatkowski D.J., Engelman J.A., Janne P.A.;
RT   "Amplification of EGFR T790M causes resistance to an irreversible EGFR
RT   inhibitor.";
RL   Oncogene 29:2346-2356(2010).
//
RX   PubMed=26828195; DOI=10.1038/nm.4040; PMCID=PMC4900892;
RA   Hata A.N., Niederst M.J., Archibald H.L., Gomez-Caraballo M.,
RA   Siddiqui F.M., Mulvey H.E., Maruvka Y.E., Ji F., Bhang H.-e.C.,
RA   Krishnamurthy Radhakrishna V., Siravegna G., Hu H.-C., Raoof S.,
RA   Lockerman E.L., Kalsy A., Lee D., Keating C.L., Ruddy D.A., Damon L.J.,
RA   Crystal A.S., Costa C., Piotrowska Z., Bardelli A., Iafrate A.J.,
RA   Sadreyev R.I., Stegmeier F., Getz G., Sequist L.V., Faber A.C.,
RA   Engelman J.A.;
RT   "Tumor cells can follow distinct evolutionary paths to become
RT   resistant to epidermal growth factor receptor inhibition.";
RL   Nat. Med. 22:262-269(2016).
//